Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17β-estradiol or equine conjugated estrogen plus nomegestrol acetate;Comparaison de l'évolution des marqueurs biologiques du remodelage osseux après six mois de traitement hormonal substitutif par 17β-estradiol cutané ou estrogènes sulfoconjugués équins et acétate de nomégestrol

Gynecologie Obstetrique et Fertilite

Volumn 31, Issue 5, 2003, Pages 434-441

  Collette, J ^a   Viethel, P ^b   Dethor, M ^a   Chevallier, T ^c   Micheletti, M C ^b   Foidart, J M ^d   Reginster, J Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Laboratoire THERAMEX   (France)

^c UNIV MONTPELLIER   (France)

^d Centre Hospitalier Regional de La Citadelle   (Belgium)

Author keywords

Bone turnover markers; Estrogen; Menopause; Nomegestrol acetate

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; CONJUGATED ESTROGEN; ESTRADIOL; ESTREVA; NOMEGESTROL ACETATE;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVITY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HORMONE DEFICIENCY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; OSTEOLYSIS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINALYSIS;

EID: 0042927975     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/S1297-9589(03)00118-8     Document Type: Article

References (37)

1. Pouillès JM, Trémollières F, Ribot C. Effect of menopause on femoral and vertebral bone loss. J Bone Miner Res 1995;10:1531-6.
2. Christiansen C, Sanvig Christensen M, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459-61.
3. The Writing Group for the Pepi Trial. Effects of hormone therapy on bone mineral density. Results from the Postmenopausal Estrogen/Progestin Interventions (Pepi Trial). J Am Med Assoc 1996; 276:1389-96.
4. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102: 319-24.
5. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
6. Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981;9:28-31.
7. Reginster JY, Janssen C, Deroisy R, Zegels B, Albert A, Franchimont P. Bone mineral density of the spine and the hip measured with Dual Energy X-ray absorptiometry: normal range and fracture threshold for Western European (Belgian) postmenopausal females. Clin Rheum 1995;14:68-75.
8. Delmas PD. Utilisation clinique des marqueurs biologiques osseux dans l'ostéoporose postménopausique. Ann Biol Clin 2001;59: 299-308.
9. Reginster JY, Henrotin Y, Christiansen C, Gamwell-Henriksen E, Bruyère O, Collette J, Christgau S. Bone resorption in postmenopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 2001;69:130-7.
10. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337-49.
11. Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP. An indicator of spontaneous bone loss and of the effect of oestrogen treatement in postmenopausal women. Eur J Clin Invest 1988;18:191-5.
12. Garnero P, Sornay-Rendu E, Duboeuf F, Demmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The Ofely Study. J Bone Miner Res 1999;14:1614-21.
13. Bjarnasson NH, Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 2000;26:561-9.
14. Rosen CJ, Chesnut III CH, Mallinak NJS. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904-10.
15. Chesnut III CH, Bell NH, Clark GS, Drinkwater BL, English SC, Johnston Jr CC, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37.
16. Dennison E, Eastel R, Fall CHD, Kellingray S, Wood PJ, Cooper C. Determinants of bone loss in elderly men and women: a prospective population-based study. Osteoporosis Int 1999;10:384-91.
17. Dresner Pollak R, Parker RA, Poku M, Thompson J, Seibel MJ, Greenspan SL. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int 1996;59:328-33.
18. Melton LJ, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL. Determinants of bone loss from the femoral neck in women of different ages. J Bone Miner Res 2000;15:24-31.
19. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: The Epidos Prospective Study. J Bone Miner Res 1996;11:1531-8.
20. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover endogenous hormones and the risk of fractures in postmenopausal women: the Ofely study. J Bone Miner Res 2000;15:1526-36.
21. Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD. Afternoon sampled serum type I collagen breakdown product (serum CTX) predicts hip fracture in elderly women: results of the Epidos study. Bone 2000;27:283-6.
22. Trémollières F, Capilla F, Cigagna F, Ribot C. Augmentation de la prolifération cellulaire par l'acétate de nomégestrol dans les cultures d'ostéoblastes humains. Reprod Hum Horm 1997;10:118-24.
23. Zartarian M, Micheletti MC, Gauthier A, Torres C, Dewailly D. Effets sur la qualité des cycles et les bouffées de chaleur du nomégestrol acétate administré seul ou associé en séquentiel inversé au 17 bêta estradiol cutané chez des femmes en périménopause. Contracept Fertil Sex 1998;26:69-76.
24. Reginster JY, Christiansen C, Dequinze B, Deroisy R, Gaspard U, Taquet AN, Franchimont P. Effect of transdermal 17β-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. Calcif Tissue Int 1993;53:13-6.
25. Riis BJ, Thomsen K, Strom V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987;156:61-5.
26. Ribot C, Trémollières F, Pouillès JM, Louvet JP, Peyron R. Preventive effects of transdermal administration of 17β-estradiol on postmenopausal bone loss: a 2-years prospective study. Gynecol Endocrinol 1989;3:259-68.
27. Garnero P, Tsouderos Y, Marton I, Pelissier C, Varin C, Delmas PD. Effects of intranasal 17β-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J Clin Endocrinol Metab 1999;84:2390-7.
28. Riis BJ, Overgaard K, Christiansen C. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteoporosis Int 1995;5:276-80.
29. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone 1999;24:237-44.
30. Ravn P, Hosking D, Thompson GC, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in early postmenopausal intervention cohort of study. J Clin Endocrinol Metab 1999;84:2363-8.
31. Garnero P, Darte C, Delmas PD. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 1999;24:603-9.
32. Delmas PD, Hardy P, Garnero P, Dain MP. Monitoring individual response to hormone replacement therapy with bone markers. Bone 2000;26:553-60.
33. Marcus R, Holloway L, Wells B. et al. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the postmenopausal estrogen/progestin interventions (Pepi) trial. J Bone Miner Res 1999;14:1583-95.
34. Delmas PD, Pornel B, Felsenberg D, et al. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. Bone 1999;24:517-23 International Study Group.
35. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. A position paper on the use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 2000;11:S2-S17.
36. Delmas PD, Bjarnasson NH, Mitkak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337: 1641-7.
37. Ross PD, Kress BC, Parson RE, et al. Serum bone alkaline phosphatase and calcaneus bone density predit fracture: a prospective study. Osteoporos Int 2000;11:76-82.